Autobahn Therapeutics Announces Successful Financing To Support Strategic Advancement Of Abx-002 For Treatment Resistant Depression
Autobahn Therapeutics Announces Successful Financing To Support Strategic Advancement Of Abx-002 For Treatment Resistant Depression
09/08/22, 12:36 PM
Location
san diegoIndustry
therapeutics
biotechnology
health care
Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the closing of a $32.7 million financing to support the company’s continued commitment to transforming the treatment of CNS disorders, led by a strategic prioritization on addressing treatment-resistant depression (TRD). Current shareholders ARCH Venture Partners, Cowen Healthcare Investments, BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital, Alexandria Venture Investments and GT Healthcare all participated in the round.
Company Info
Location
san diego, california, united states
Additional Info
Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders. Leveraging its proprietary brain-targeting chemistry platform, Autobahn aims to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist, being developed initially for people with treatment-resistant depression. Autobahn Therapeutics is based in San Diego.